Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to compare the effects of Genz-644470 with the effects
of placebo and sevelamer carbonate (Renvela®) on the reduction of serum phosphorus in
hyperphosphatemic chronic kidney disease participants on hemodialysis.